Tenaya insider sells 1.905M and 161k shares

Tenaya Therapeutics reported insider sales by Column Group III, LP in two transactions.

Rhea-AI Filing Summary

Tenaya Therapeutics reported insider sales by Column Group III, LP in two transactions.

The filing lists a sale of 161,422 shares on 02/10/2026 for $131,736.49 and a sale of 1,905,115 shares on 02/11/2026 for $1,297,002.29.

Insights

Insider Transaction Analyst

Two large resale transactions by an affiliate are reported, with exact share counts and proceeds disclosed.

The excerpt shows Column Group III, LP sold 161,422 shares on 02/10/2026 for $131,736.49 and 1,905,115 shares on 02/11/2026 for $1,297,002.29.

These are reported resale transactions; the filing lists sale dates and gross proceeds. Subsequent SEC filings or broker reports may disclose additional context about the seller's relationship to Tenaya or whether further transactions follow.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who sold shares in the Tenaya (TNYA) Form 144 filing?

The filing shows Column Group III, LP as the selling party. It lists two transactions with sales dated 02/10/2026 and 02/11/2026.

How many Tenaya (TNYA) shares were sold on 02/10/2026 and 02/11/2026?

On 02/10/2026, 161,422 shares were sold for $131,736.49. On 02/11/2026, 1,905,115 shares were sold for $1,297,002.29.

What proceeds were reported from the Tenaya (TNYA) sales?

The excerpt reports proceeds of $131,736.49 for the 02/10/2026 sale and $1,297,002.29 for the 02/11/2026 sale, as shown in the filing.

Does the filing state who received the sale proceeds for Tenaya (TNYA)?

The filing attributes the transactions to Column Group III, LP and lists gross proceeds for each sale. It does not attach a secondary payee label beyond the selling holder shown in the excerpt.

Were the sold Tenaya (TNYA) shares part of earlier financings listed in the excerpt?

The excerpt includes prior issuance lines referencing Series A financings dated 07/31/2017 and 12/20/2018, but it does not explicitly tie the two reported sales to those financings within the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:37 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001668159
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Tenaya Therapeutics, Inc.
SEC File Number	001-40656
Address of Issuer	171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	415-865-2066
Name of Person for Whose Account the Securities are To Be Sold	COLUMN GROUP III, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	BTIG, LLC 350 Bush Street 9th Floor San Francisco CA 94104	1408910	872537.96	213744535	02/20/2026	NASDAQ GS

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/31/2017	Series A financing	Tenaya Therapeutics			200028	07/31/2017	Cash
Common	12/20/2018	Series A financing	Tenaya Therapeutics			1208882	12/20/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
COLUMN GROUP III, LP 1 Letterman Drive Suite DM-900 San Francisco CA 94129	Common	02/10/2026	161422	131736.49
COLUMN GROUP III, LP 1 Letterman Drive, Suite DM-900 San Francisco CA 94129	Common	02/11/2026	1905115	1297002.29

144: Remarks and Signature

Remarks
Date of Notice	02/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Evangelista
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)